Hepatitis Monthly

Published by: Kowsar

Hepatitis B Vaccination: Needs a Revision

Mohammad Saeid Rezaee-Zavareh 1 , 2 and Behzad Einollahi 3 , *
Authors Information
1 Students’ Research Committee, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
2 Middle East Liver Disease Center, Tehran, IR Iran
3 Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: March 01, 2014, 14 (3); e17461
  • Published Online: March 11, 2014
  • Article Type: Editorial
  • Received: January 8, 2014
  • Accepted: January 8, 2014
  • DOI: 10.5812/hepatmon.17461

To Cite: Rezaee-Zavareh M S, Einollahi B. Hepatitis B Vaccination: Needs a Revision, Hepat Mon. 2014 ; 14(3):e17461. doi: 10.5812/hepatmon.17461.

Copyright © 2014, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Hepatitis B virus Infection, Epidemiology and Complications
2. History of HBV Vaccine and Its Generations
3. Special Groups Needs Special Attention
4. The Present Situation Several Years After Starting the Successful HBV Vaccination Program
Acknowledgements
Footnotes
References
  • 1. Edey M, Barraclough K, Johnson DW. Review article: Hepatitis B and dialysis. Nephrology (Carlton). 2010; 15(2): 137-45[DOI][PubMed]
  • 2. Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int. 2009; 29 Suppl 1: 100-7[DOI][PubMed]
  • 3. Global alert and response. Hepatitis B.
  • 4. Grzegorzewska AE. Hepatitis B vaccination in chronic kidney disease: review of evidence in non-dialyzed patients. Hepat Mon. 2012; 12(11)[DOI][PubMed]
  • 5. Aspinall EJ, Hawkins G, Fraser A, Hutchinson SJ, Goldberg D. Hepatitis B prevention, diagnosis, treatment and care: a review. Occup Med (Lond). 2011; 61(8): 531-40[DOI][PubMed]
  • 6. Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. Int J Infect Dis. 2012; 16(2)-8[DOI][PubMed]
  • 7. Schillie SF, Murphy TV. Seroprotection after recombinant hepatitis B vaccination among newborn infants: a review. Vaccine. 2013; 31(21): 2506-16[DOI][PubMed]
  • 8. Schillie SF, Spradling PR, Murphy TV. Immune response of hepatitis B vaccine among persons with diabetes: a systematic review of the literature. Diabetes Care. 2012; 35(12): 2690-7[DOI][PubMed]
  • 9. Sempere L, Almenta I, Barrenengoa J, Gutierrez A, Villanueva CO, de-Madaria E, et al. Factors predicting response to hepatitis B vaccination in patients with inflammatory bowel disease. Vaccine. 2013; 31(30): 3065-71[DOI][PubMed]
  • 10. Whitaker JA, Rouphael NG, Edupuganti S, Lai L, Mulligan MJ. Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. Lancet Infect Dis. 2012; 12(12): 966-76[DOI][PubMed]
  • 11. Sangkomkamhang US, Lumbiganon P, Laopaiboon M. Hepatitis B vaccination during pregnancy for preventing infant infection. Cochrane Database Syst Rev. 2011; (3)[DOI][PubMed]
  • 12. Einollahi B. Immune response to hepatitis B vaccine in patients with chronic kidney disease. Hepat Mon. 2011; 11(10): 781-2[DOI][PubMed]
  • 13. Fabrizi F, Dixit V, Martin P. Meta-analysis: the adjuvant role of thymopentin on immunological response to hepatitis B virus vaccine in end-stage renal disease. Aliment Pharmacol Ther. 2006; 23(11): 1559-66[DOI][PubMed]
  • 14. Fabrizi F, Dixit V, Martin P, Messa P. Erythropoietin use and immunogenicity of hepatitis B virus vaccine in chronic kidney disease patients: a meta-analysis. Kidney Blood Press Res. 2012; 35(6): 504-10[DOI][PubMed]
  • 15. Sanadgol H. Levamisole usage as an adjuvant to hepatitis B vaccine in hemodialysis patients, yes or no? Nephrourol Mon. 2013; 5(1): 673-8[DOI][PubMed]
  • 16. Yassin MH, Gupta V. Role of infection control in prevention of hepatitis B virus (HBV) in hemodialysis (HD) patients. Infect Disord Drug Targets. 2013; 13(3): 162-8[PubMed]
  • 17. Pol S, Legendre C, Mattlinger B, Berthelot P, Kreis H. Genetic basis of nonresponse to hepatitis B vaccine in hemodialyzed patients. J Hepatol. 1990; 11(3): 385-7[PubMed]
  • 18. Ahuja TS, Kumar S, Mansoury H, Rodriguez H, Kuo YF. Hepatitis B vaccination in human immunodeficiency virus-infected adults receiving hemodialysis. Kidney Int. 2005; 67(3): 1136-41[DOI][PubMed]
  • 19. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease. Aliment Pharmacol Ther. 2004; 20(10): 1053-62[DOI][PubMed]
  • 20. Fernandez E, Betriu MA, Gomez R, Montoliu J. Response to the hepatitis B virus vaccine in haemodialysis patients: influence of malnutrition and its importance as a risk factor for morbidity and mortality. Nephrol Dial Transplant. 1996; 11(8): 1559-63[PubMed]
  • 21. Navarro JF, Teruel JL, Mateos ML, Marcen R, Ortuno J. Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. Am J Nephrol. 1996; 16(2): 95-7[PubMed]
  • 22. Afsar B. The relationship between erythropoietin resistance and antibody response to hepatitis B vaccine in hemodialysis patients. Nephrourol Mon. 2013; 5(3): 806-12[DOI][PubMed]
  • 23. Fabrizi F, Dixit V, Magnini M, Elli A, Martin P. Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. Aliment Pharmacol Ther. 2006; 24(3): 497-506[DOI][PubMed]
  • 24. Al Ghamdi SS, Fallatah HI, Fetyani DM, Al-Mughales JA, Gelaidan AT. Long-term efficacy of the hepatitis B vaccine in a high-risk group. J Med Virol. 2013; 85(9): 1518-22[DOI][PubMed]
  • 25. Bian T, Yan H, Shen L, Wang F, Zhang S, Cao Y, et al. Change in hepatitis B virus large surface antigen variant prevalence 13 years after implementation of a universal vaccination program in China. J Virol. 2013; 87(22): 12196-206[DOI][PubMed]
  • 26. Chiara F, Bartolucci GB, Cattai M, Piazza A, Nicolli A, Buja A, et al. Hepatitis B vaccination of adolescents: Significance of non-protective antibodies. Vaccine. 2013; 32(1): 62-8[DOI][PubMed]
  • 27. Elrashidy H, Elbahrawy A, El-Didamony G, Mostafa M, George NM, Elwassief A, et al. Antibody levels against hepatitis B virus after hepatitis B vaccination in Egyptian diabetic children and adolescents. Hum Vaccin Immunother. 2013; 9(9): 2002-6[DOI][PubMed]
  • 28. Masuet-Aumatell C, Ramon-Torrell JM, Casanova-Rituerto A, Banque-Navarro M, Davalos-Gamboa Mdel R, Rodriguez SL. Seroprevalence of hepatitis B in two period birth cohorts of Bolivian children: effect of universal vaccination. Trans R Soc Trop Med Hyg. 2013; 107(9): 578-83[DOI][PubMed]
  • 29. Mizusawa M, Perlman DC, Lucido D, Salomon N. Rapid loss of vaccine-acquired hepatitis B surface antibody after three doses of hepatitis B vaccination in HIV-infected persons. Int J STD AIDS. 2013; [DOI][PubMed]
  • 30. Nisihara R, De Bem RS, Negreiros PH, Utiyama SR, Oliveira NP, Amarante H. Low hepatitis B vaccine response in children with Down syndrome from Brazil. Child Care Health Dev. 2013; [DOI][PubMed]
  • 31. Roni DA, Pathapati RM, Kumar AS, Nihal L, Sridhar K, Tumkur Rajashekar S. Safety and efficacy of hepatitis B vaccination in cirrhosis of liver. Adv Virol. 2013; 2013: 196704[DOI][PubMed]
  • 32. Kaltsas A, Sepkowitz K. Vaccinations for healthcare personnel: update on influenza, hepatitis B, and pertussis. Curr Opin Infect Dis. 2013; 26(4): 366-77[DOI][PubMed]
  • 33. Yildiz N, Sever L, Kasapcopur O, Cullu F, Arisoy N, Caliskan S. Hepatitis B virus vaccination in children with steroid sensitive nephrotic syndrome: immunogenicity and safety? Vaccine. 2013; 31(33): 3309-12[DOI][PubMed]
  • 34. Rendi-Wagner P, Shouval D, Genton B, Lurie Y, Rumke H, Boland G, et al. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine. 2006; 24(15): 2781-9[DOI][PubMed]
  • 35. Saade F, Honda-Okubo Y, Trec S, Petrovsky N. A novel hepatitis B vaccine containing Advax, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. Vaccine. 2013; 31(15): 1999-2007[DOI][PubMed]
  • 36. Eng NF, Bhardwaj N, Mulligan R, Diaz-Mitoma F. The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV review. Hum Vaccin Immunother. 2013; 9(8): 1661-72[DOI][PubMed]
  • 37. Kuan RK, Janssen R, Heyward W, Bennett S, Nordyke R. Cost-effectiveness of hepatitis B vaccination using HEPLISAV in selected adult populations compared to Engerix-B(R) vaccine. Vaccine. 2013; 31(37): 4024-32[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments